Abstract:Despite the availability of vaccines, influenza remains a major public health challenge. A key reason is the virus capacity for immune escape: ongoing evolution allows the continual circulation of seasonal influenza, while novel influenza viruses invade the human population to cause a pandemic every few decades. Current vaccines have to be updated continually to keep up to date with this antigenic change, but emerging 'universal' vaccines-targeting more conserved components of the influenza virus-offer the potential to act across all influenza A strains and subtypes. Influenza vaccination programmes around the world are steadily increasing in their population coverage. In future, how might intensive, routine immunization with novel vaccines compare against similar mass programmes utilizing conventional vaccines? Specifically, how might novel and conventional vaccines compare, in terms of cumulative incidence and rates of antigenic evolution of seasonal influenza? What are their potential implications for the impact of pandemic emergence? Here we present a new mathematical model, capturing both transmission dynamics and antigenic evolution of influenza in a simple framework, to explore these questions. We find that, even when matched by per-dose efficacy, universal vaccines could dampen population-level transmission over several seasons to a greater extent than conventional vaccines. Moreover, by lowering opportunities for cross-protective immunity in the population, conventional vaccines could allow the increased spread of a novel pandemic strain. Conversely, universal vaccines could mitigate both seasonal and pandemic spread. However, where it is not possible to maintain annual, intensive vaccination coverage, the duration and breadth of immunity raised by universal vaccines are critical determinants of their performance relative to conventional vaccines. In future, conventional and novel vaccines are likely to play complementary roles in vaccination strategies against influenza: in this context, our results suggest important characteristics to monitor during the clinical development of emerging vaccine technologies.

Computer-assisted vaccine design

Quantifying influenza vaccine efficacy and antigenic distance

A Novel Sequence-Based Antigenic Distance Measure for H1N1, with Application to Vaccine Effectiveness and the Selection of Vaccine Strains

Early Recognition of Emerging Flu Strain Clusters

Antigenic distance measurements for seasonal influenza vaccine selection

Prediction of Influenza B Vaccine Effectiveness from Sequence Data

A sequence-based machine learning model for predicting antigenic distance for H3N2 influenza virus

Using sequence data to infer the antigenicity of influenza virus

Leveraging Pre-Vaccination Antibody Titers across Multiple Influenza H3N2 Variants to Forecast the Post-Vaccination Response

A computational framework for influenza antigenic cartography

Mapping of H3N2 Influenza Antigenic Evolution in China Reveals a Strategy for Vaccine Strain Recommendation

Modeling the Antigenic Evolution of Seasonal Influenza Viruses with PREDAC for Vaccine Strain Selection in the Season of 2025

Influenza Virus Vaccine Efficacy Based On Conserved Sequence Alignment

Influenza B Virus Vaccine Innovation through Computational Design

Concepts and applications for influenza antigenic cartography

Predicting Influenza Antigenicity by Matrix Completion with Antigen and Antiserum Similarity

Incorporating structure context of HA protein to improve antigenicity calculation for influenza virus A/H3N2

A general solution to broad-spectrum vaccine design for rapidly mutating viruses

Using Pathogen Genomics to Predict Antigenic Changes of Influenza H3N2 Virus

Global antigenic landscape and vaccine recommendation strategy for low pathogenic avian influenza A (H9N2) viruses

Universal or Specific? A Modeling-Based Comparison of Broad-Spectrum Influenza Vaccines against Conventional, Strain-Matched Vaccines